Who
Brenda Cooperstone
Director
Company insider
Files Form 4 as: Director, Lexeo Therapeutics; Director, Senti Biosciences Holdings.
In numbers
- Trades disclosed
- 9
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 13 Jul 2022
- Last trade
- 25 Jun 2026
- Last filed
- 29 Jun 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 25 Jun 2026filed 29 Jun 2026 | LXEO Lexeo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 25 Jun 2026filed 29 Jun 2026 | LXEO Lexeo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 26 Jun 2025filed 30 Jun 2025 | LXEO Lexeo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 25 Jun 2025filed 27 Jun 2025 | SNTI Senti Biosciences Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,950 at $0.00 | filing |
| 7 Mar 2025filed 11 Mar 2025 | SNTI Senti Biosciences Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —43,900 at $0.00 | filing |
| 10 Jul 2024filed 12 Jul 2024 | SNTI Senti Biosciences Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —62,500 at $0.00 | filing |
| 25 Jun 2024filed 27 Jun 2024 | LXEO Lexeo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,000 at $0.00 | filing |
| 16 Jun 2023filed 21 Jun 2023 | SNTI Senti Biosciences Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —62,500 at $0.00 | filing |
| 13 Jul 2022filed 15 Jul 2022 | SNTI Senti Biosciences Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.